Phase 2b clinical trial results of TC-5214 to be presented at nAChR2009

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today confirmed plans to present data from its completed Phase 2b clinical trial of TC-5214 as an augmentation treatment for major depressive disorder at the Nicotinic Acetylcholine Receptors as Therapeutic Targets Symposium (nAChR2009) in Lincolnshire, Illinois on October 15, 2009. Additionally, Targacept announced that data regarding AZD3480 (TC-1734) and TC-5619 are also scheduled to be presented at nAChR2009.

nAChR2009 is a satellite meeting of the 39^th annual meeting of the Society for Neuroscience. The full agenda and registration information for nAChR2009 can be found at https://www.cmpinc.net/nicotinic/home.html.

The scheduled presentations include:

• Title: “From MCI to ADHD: Targeting nAChRs for cognitive/attention disorders”
  Presenter: Paul Newhouse, University of Vermont College of Medicine
  Date/Time: October 15, 2009, 10:30 – 11:00 a.m. CDT
  
  Dr. Newhouse was co-Principal Investigator for the completed Phase 2 clinical study of AZD3480 in adults with attention deficit/hyperactivity disorder. Targacept announced positive top-line results from the study earlier this year.

• Title: “Clinical Update: AZD3480 / TC-1734”
  Presenter: Edwin C. Johnson, Ph.D., AstraZeneca
  Date/Time: October 15, 2009, 11:30 a.m. – 12:00 noon CDT

• Title: “TC-5619: An α7 nAChR selective agonist with efficacy in animal models of positive and negative symptoms, and cognitive dysfunction of schizophrenia”
  Presenter: Patrick M. Lippiello, Ph.D., Targacept, Inc.
  Date/Time: October 15, 2009, 2:00 –2:30 p.m. CDT

• Title: “Positive effects of the nicotinic channel blocker TC-5214 as augmentation treatment in patients with major depressive disorder who are inadequate responders to a first-line SSRI”
  Presenter: Geoffrey C. Dunbar, M.D., Targacept, Inc.
  Date/Time: October 15, 2009, 5:00 – 5:30 p.m. CDT

http://www.targacept.com/